glp 1 companies to invest in GLP-1 Drugs Drop More Than Just Weight 6 Best Weight Loss Stocks

In 2025, pharma companies are witnessing unprecedented growth in the obesity drug market, with GLP-1 receptor agonists leading the way

Novo Nordisks amycretin (oral) and CagriSema (amylin/GLP-1 dual agonist) , as well as Zealand Pharmas petrelintide , are showing encouraging results and potential for combination therapies with GLP-1s

49 GLP-1RA is primarily used for the treatment of T2DM 68 and works by mimicking the action of the naturally occurring hormone GLP-1, which is released by the intestines in response to food intake

And theres no better ingredient for that than MOROSIL awarded Ingredient of the Year in the Weight Management category